<DOC>
	<DOCNO>NCT00633399</DOCNO>
	<brief_summary>The purpose study see add study drug , ziprasidone , antidepressant medication help improve symptom Major Depressive Disorder ( MDD ) . We study drug 's effectiveness treat depression , well safety add another drug . Hypothesis A : There difference percentage responder two treatment condition phase 2 ; response rate higher ziprasidone group .</brief_summary>
	<brief_title>Ziprasidone Augmentation SSRIs Patients With Major Depressive Disorder ( MDD ) That Not Sufficiently Respond Treatment With SSRIs</brief_title>
	<detailed_description>The propose study involve three phase . The first phase 8-week , open-label trial SSRI MDD . Patients experience sufficient symptom improvement follow open-label trial enrol 6-week , double-blind , placebo control trial ziprasidone augmentation ( second phase ) . Ziprasidone placebo-remitters enter 12-month , double-blind extension phase ( third phase ) . We estimate approximately 400 patient enter phase 1 study minimum 180 subject enter double-blind treatment ( phase 2 ) 5 year . Each treatment arm phase 2 90 subject . Hypothesis B1 : During phase 2 , difference two group percentage responder ( 50 % great reduction symptom severity ) regard anxious symptom MDD measure 14-item Hamilton Anxiety Rating Scale ( HAM-A ) ; response rate higher ziprasidone group . Hypothesis B2 : During phase 2 , difference two group percentage responder ( 50 % great reduction symptom severity ) regard painful symptom MDD , measure overall visual analogue pain ( VAS-pain ) scale score ; response rate higher ziprasidone group . Hypothesis C : The time relapse phase 3 shorter among adjunctive placebo- ziprasidone-remitters .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Ziprasidone</mesh_term>
	<mesh_term>Serotonin Uptake Inhibitors</mesh_term>
	<criteria>Written inform consent . Men woman , 1865 year age . MDD , current , accord DSMIV criterion diagnose SCID I/P screen baseline visit phase 1 . A HAMD17 score &gt; 14 screen baseline visit phase 1 . Pregnant woman woman child bear potential use medically accept mean contraception ( oral contraceptive implant , condom , diaphragm , spermicide , intrauterine Device , tubal ligation , partner vasectomy ) . Serious suicide homicide risk , assess evaluate clinician . Unstable medical illness include cardiovascular , hepatic , renal , respiratory , endocrine , neurological , hematological disease uncontrolled seizure disorder . History multiple adverse drug reaction allergy study drug . The following DSMIV diagnosis : substance use disorder active within last six month , bipolar disorder ( current past ) , psychotic disorder ( current past ) . Patients require excluded medication ( see appendix 1 detail ) . Psychotic feature current episode history psychotic feature . Prior course ziprasidone , intolerance ziprasidone dose . Any investigational psychotropic drug within last 3 month . Have fail 3 adequate antidepressant trial current MDE . Some example adequate dosage antidepressant trial include either &gt; 150 mg imipramine ( tricyclic equivalent ) , &gt; 60 mg phenelzine ( monoamine oxidase inhibitor equivalent ) , &gt; 20 mg fluoxetine ( SSRIequivalent ) , &gt; 150mg bupropion , &gt; 300mg trazodone ( nefazodone ) , &gt; 75 mg venlafaxine , &gt; 60mg duloxetine , &gt; 15mg mirtazapine . A trial adequate duration define one patient give antidepressant adequate dose minimum 6 week .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Major Depressive Disorder</keyword>
	<keyword>Major Depression</keyword>
	<keyword>Depression</keyword>
	<keyword>Geodon</keyword>
	<keyword>Ziprasidone</keyword>
	<keyword>SSRI Augmentation</keyword>
	<keyword>Treatment Resistant Depression</keyword>
</DOC>